Cited by 141Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesAcute Lymphoblastic Leukemia research

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial

Milligan, Donald W., Wheatley, Keith, Littlewood, Timothy, Craig, Jenny I. O., Burnett, Alan K., for the NCRI Haematological Oncology Clinical Studies Group·2006·Blood

DOI 10.1182/blood-2005-10-4202

Open this paper in CoChat — free account

Abstract

The optimum chemotherapy schedule for reinduction of patients with high-risk acute myeloid leukemia (relapsed, resistant/refractory, or adverse genetic disease) is uncertain. The MRC AML (Medical Research Council Acute Myeloid Leukemia) Working Group designed a trial comparing fludarabine and high-dose cytosine (FLA) with standard chemotherapy comprising cytosine arabinoside, daunorubicin, and etoposide (ADE). Patients were also randomly assigned to receive filgrastim (G-CSF) from day 0 until neutrophil count was greater than 0.5 × 109/L (or for a maximum of 28 days) and all-trans retinoic acid (ATRA) for 90 days. Between 1998 and 2003, 405 patients were entered: 250 were randomly assigned between FLA and ADE; 356 to G-CSF versus no G-CSF; 362 to ATRA versus no ATRA. The complete remission rate was 61% with 4-year disease-free survival of 29%. There were no significant differences in the CR rate, deaths in CR, relapse rate, or DFS between ADE and FLA, although survival at 4 years was worse with FLA (16% versus 27%, P = .05). Neither the addition of ATRA nor G-CSF demonstrated any differences in the CR rate, relapse rate, DFS, or overall survival between the groups. In conclusion these findings indicate that FLA may be inferior to standard chemotherapy in high-risk AML and that the outcome is not improved with the addition of either G-CSF or ATRA.

Integrity signals

Registry

Crossref · 10.1182/blood-2005-10-4202

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3558 · Cited by 1,044
High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy
Campos, L., Rouault, J., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J., & Guyotat, D. (1993) · Blood · doi:10.1182/blood.v81.11.3091.3091 · Cited by 783
Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission
Cassileth, P. A., Harrington, D. P., Appelbaum, F. R., Lazarus, H. M., Rowe, J. M., Paietta, E. M., Willman, C. L., Hurd, D. D., Bennett, J. M., Blume, K. G., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812033392301 · Cited by 607
Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial
Burnett, A. K., Goldstone, A. H., Stevens, R., Hann, I. M., Rees, J. K. H., Gray, R. G., & Wheatley, K. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09214-3 · Cited by 560
Self-citation
Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse
Breems, D. A., van Putten, W. L. J., Huijgens, P. C., Ossenkoppele, G. J., Verhoef, G. E. G., Verdonck, L. F., Vellenga, E., de Greef, G. E., Jacky, E., der Lelie, J. V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.027 · Cited by 510
Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia
Stone, R. M., Berg, D. T., George, S. L., Dodge, R. K., Paciucci, P. A., Schulman, P., Lee, E. J., Moore, J. O., Powell, B. L., & Schiffer, C. A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322503 · Cited by 447
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
Goldstone, A. H., Burnett, A. K., Wheatley, K., Smith, A. G., Hutchinson, R. M., & Clark, R. E. (2001) · Blood · doi:10.1182/blood.v98.5.1302 · Cited by 437
Self-citation
A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial
Wheatley, K., Burnett, A. K., Goldstone, A. H., Gray, R. G., Hann, I. M., Harrison, C. J., Rees, J. K. H., Stevens, R., & Walker, H. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01684.x · Cited by 432
Self-citation
Acute promyelocytic leukemia: evolving therapeutic strategies
Tallman, M. S., Nabhan, C., Feusner, J. H., & Rowe, J. M. (2002) · Blood · doi:10.1182/blood.v99.3.759 · Cited by 395

Show all 49 references

Research works printed but not linked: 1

Visani G, Tosi P, Zinzani PL, et al. FLAG: an effective and tolerable protocol for the treatment of “poor-risk” acute myeloid leukemia. Leukemia. 1994;8: 1842-1846.

Sorted by citations

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438
Self-citation
Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML
Saito, Y., Uchida, N., Tanaka, S., Suzuki, N., Tomizawa-Murasawa, M., Sone, A., Najima, Y., Takagi, S., Aoki, Y., Wake, A., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1607 · Cited by 433
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
Vetrie, D. L. P., Helgason, G. V., & Copland, M. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-019-0230-9 · Cited by 365
How I treat refractory and early relapsed acute myeloid leukemia
Thol, F. R., Schlenk, R. F., Heuser, M., & Ganser, A. (2015) · Blood · doi:10.1182/blood-2014-10-551911 · Cited by 307
Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group
Lange, B. J., Smith, F. O., Feusner, J. H., Barnard, D., Dinndorf, P. A., Feig, S. A., Heerema, N. A., Arndt, C., Arceci, R. J., Seibel, N. L., et al. (2007) · Blood · doi:10.1182/blood-2007-04-084293 · Cited by 274
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B
Schlenk, R. F., Dohner, K., Kneba, M., Gotze, K., Hartmann, F., del Valle, F., Kirchen, H., Koller, E., Fischer, J. T., Bullinger, L., et al. (2009) · Haematologica · doi:10.3324/haematol.13378 · Cited by 210
Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection
Sung, L., Nathan, P. C., Alibhai, S. M. H., TOMLINSON, G. A., & Beyene, J. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-6-200709180-00010 · Cited by 189
Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial
Faderl, S. H., Wetzler, M., Rizzieri, D. A., Schiller, G. J., Jagasia, M., Stuart, R. K., Ganguly, S., Avigan, D., Craig, M., Collins, R. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.9743 · Cited by 176
Unlocking the potential of retinoic acid in anticancer therapy
Schenk, T., Stengel, S., & Zelent, A. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.412 · Cited by 160
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
Ravandi, F., Ritchie, E. K., Sayar, H., Lancet, J. E., Craig, M., Vey, N., Strickland, S. A., Schiller, G. J., Jabbour, E. J., Erba, H. P., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00201-6 · Cited by 157
Current and emerging therapies for acute myeloid leukemia
Robak, T., & Wierzbowska, A. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.11.017 · Cited by 154
Guidelines on the management of acute myeloid leukaemia in adults
Milligan, D. W., Grimwade, D. J., Cullis, J., Bond, L., Swirsky, D. M., Craddock, C., Kell, J., Homewood, J., Campbell, K. L., McGinley, S., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06314.x · Cited by 149
Self-citation
The success and the challenge of all-trans retinoic acid in the treatment of cancer
Ni, X., Hu, G., & Cai, X. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1509201 · Cited by 149
MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML
Heuser, M., Argiropoulos, B., Kuchenbauer, F. C., Yung, E., Piper, J., Fung, S., Schlenk, R. F., Döhner, K., Hinrichsen, T., Rudolph, C., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080523 · Cited by 149
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G‐CSF (CLAG‐M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group
Wierzbowska, A., Robak, T., Pluta, A., Wawrzyniak, E., Cebula‐Obrzut, B., Hołowiecki, J., Kyrcz‐Krzemień, S., Grosicki, S., Giebel, S., Skotnicki, A. B., et al. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.00988.x · Cited by 141
Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers
Francia, R. D., Crisci, S., Monaco, A. D., Cafiero, C., Re, A., Iaccarino, G., Filippi, R. D., Frigeri, F., Corazzelli, G., Micera, A., et al. (2021) · Cancers · doi:10.3390/cancers13050966 · Cited by 143
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808
Kolitz, J. E., George, S. L., Marcucci, G., Vij, R., Powell, B. L., Allen, S. L., DeAngelo, D. J., Shea, T. C., Stock, W., Baer, M. R., et al. (2010) · Blood · doi:10.1182/blood-2009-07-229492 · Cited by 129
Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Promote Malignant Growth of Cells from Head and Neck Squamous Cell Carcinomas In vivo
Gutschalk, C. M., Herold‐Mende, C. C., Fusenig, N. E., & Mueller, M. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0158 · Cited by 129
Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Ramos, N. R., Mo, C. C., Karp, J. E., & Hourigan, C. S. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4040665 · Cited by 127
Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure
Wattad, M. A., Weber, D., Döhner, K., Krauter, J., Gaidzik, V. I., Paschka, P., Heuser, M., Thol, F. R., Kindler, T., Lübbert, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.23 · Cited by 116
Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review
Megías‐Vericat, J. E., Martínez‐Cuadrón, D., Sanz, M. Á., & Montesinos, P. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3304-y · Cited by 115
The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA
Burnett, A. K., Hills, R. K., Green, C. L., Jenkinson, S., Koo, K., Patel, Y., Guy, C., Gilkes, A., Milligan, D. W., Goldstone, A. H., et al. (2009) · Blood · doi:10.1182/blood-2009-08-236588 · Cited by 114
Self-citation
Why has demand for platelet components increased? A review
Estcourt, L. J. (2014) · Transfusion Medicine · doi:10.1111/tme.12155 · Cited by 111
Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia
Raghavan, M., Smith, L., Lillington, D. M., Chaplin, T., Kakkas, Ι., Molloy, G. Y., Chelala, C., Cazier, J., Cavenagh, J. D., Fitzgibbon, J., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132431 · Cited by 107
To wake up cancer stem cells, or to let them sleep, that is the question
Takeishi, S., & Nakayama, K. I. (2016) · Cancer Science · doi:10.1111/cas.12958 · Cited by 103
Safety and Efficacy of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Pediatric Acute Myeloid Leukemia: A Report From The Children's Oncology Group
Aplenc, R., Alonzo, T. A., Gerbing, R. B., Lange, B. J., Hurwitz, C. A., Wells, R. J., Bernstein, I. D., Buckley, P. J., Krimmel, K., Smith, F. O., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.0096 · Cited by 92
Differentiation therapy of myeloid leukemia: four decades of development
Madan, V., & Koeffler, H. P. (2020) · Haematologica · doi:10.3324/haematol.2020.262121 · Cited by 72
A review of treatment options employed in relapsed/refractory AML
Jiffry, M. Z. M., Kloss, R. A., Ahmed-Khan, M. A., Pires, F. C., Okam, N., Weeraddana, P., Dharmaratna, D., Dandwani, M., & Moin, K. (2023) · Hematology · doi:10.1080/16078454.2023.2196482 · Cited by 72
All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment
Su, M., Alonso, S., Jones, J. W., Yu, J., Kane, M. A., Jones, R. J., & Ghiaur, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127790 · Cited by 68
DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy
Grishina, O., Schmoor, C., Döhner, K., Hackanson, B. W., Lubrich, B., May, A. M., Cieslik, C., Müller, M. J., & Lübbert, M. (2015) · BMC Cancer · doi:10.1186/s12885-015-1432-5 · Cited by 67
Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy
Dobrotkova, V., Chlapek, P., Mazánek, P., Štěrba, J., & Veselská, R. (2018) · BMC Cancer · doi:10.1186/s12885-018-4966-5 · Cited by 67
All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study
for the German-Austrian Acute Myeloid Leukemia Study Group, Schlenk, R. F., Lübbert, M., Benner, A., Lamparter, A., Krauter, J., Herr, W., Martin, H., Salih, H. R., Kündgen, A., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2810-z · Cited by 65
Self-citation
Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Tayari, M. M., Santos, H. G. D., Kwon, D., Bradley, T., Thomassen, A., Chen, C. Y., Dinh, Y. T., Perez, A., Zelent, A., Morey, L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4054 · Cited by 53
An ATRActive future for differentiation therapy in AML
Johnson, D. E., & Redner, R. L. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.01.002 · Cited by 53
Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia
Gurion, R., Belnik, Y., Gafter‐Gvili, A., Paul, M., Vidal, L., Ben‐Bassat, I., Shpilberg, O., & Raanani, P. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008238.pub3 · Cited by 51
Mitochondrial Metabolism Inhibitors for Cancer Therapy
Ramsay, E. E., Hogg, P. J., & Dilda, P. J. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0584-5 · Cited by 52
Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies‐ The ATHENA study
Estcourt, L. J., Stanworth, S. J., Harrison, P., Powter, G., McClure, M., Murphy, M. F., & Mumford, A. D. (2014) · British Journal of Haematology · doi:10.1111/bjh.12928 · Cited by 49
Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation
van Gils, N., Verhagen, H. J. M. P., & Smit, L. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.04.007 · Cited by 49
Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid
Verhagen, H. J. M. P., Smit, M. A., Rutten, A. P., Denkers, F., Poddighe, P. J., Merle, P. A., Ossenkoppele, G. J., & Smit, L. (2015) · Blood · doi:10.1182/blood-2015-07-653840 · Cited by 47
Harnessing the benefits of available targeted therapies in acute myeloid leukaemia
Kantarjian, H. M., Short, N. J., DiNardo, C., Stein, E. M., Daver, N., Perl, A. E., Wang, E. S., Wei, A., & Tallman, M. S. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00270-2 · Cited by 43
MEK blockade converts AML differentiating response to retinoids into extensive apoptosis
Milella, M., Konopleva, M. Y., Precupanu, C., Tabe, Y., Ricciardi, M. R., Gregorj, C., Collins, S. J., Carter, B. Z., D’Angelo, C., Petrucci, M. T., et al. (2006) · Blood · doi:10.1182/blood-2006-05-024679 · Cited by 42
The prevalent predicament of relapsed acute myeloid leukemia
Szer, J. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.43.3798183 · Cited by 42
Going Beyond 7 + 3 Regimens in the Treatment of Adult Acute Myeloid Leukemia
Tefferi, A., & Letendre, L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9601 · Cited by 42
Topoisomerase II inhibitors in AML: past, present, and future
Economides, M. P., McCue, D. A., Borthakur, G. M., & Pemmaraju, N. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1621292 · Cited by 41
Randomized placebo‐controlled trial of granulocyte colony stimulating factor (G‐CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party
Wheatley, K., Goldstone, A. H., Littlewood, T. J., Hunter, A. E., & Burnett, A. K. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07710.x · Cited by 39
Self-citation
Challenges in Treating Older Patients with Acute Myeloid Leukemia
Lagadinou, E. D., Nicholas, Z. C., & Spyridonidis, A. (2010) · Journal of Oncology · doi:10.1155/2010/943823 · Cited by 39
Targeted therapy in acute myeloid leukaemia: current status and future directions
Stapnes, C., Gjertsen, B. T., Reikvam, H., & Bruserud, Ø. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220902787628 · Cited by 38
In vivobiological effects of ATRA in the treatment of AML
Ryningen, A., Stapnes, C., Rye, K. P., Lassalle, P., Gjertsen, B. T., & Bruserud, Ø. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.11.1623 · Cited by 36
The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away
Nagai, Y., & Ambinder, A. J. (2023) · Cancers · doi:10.3390/cancers15143535 · Cited by 35
Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG
Fiegl, M., Unterhalt, M., Kern, W., Braess, J., Spiekermann, K., Staib, P., Grüneisen, A., Wormann, B. J., Schöndube, D., Serve, H. L., et al. (2013) · Leukemia · doi:10.1038/leu.2013.297 · Cited by 34
Diptoindonesin G promotes ERK-mediated nuclear translocation of p-STAT1 (Ser727) and cell differentiation in AML cells
Gao, J., Fan, M., Xiang, G., Wang, J., Zhang, X., Guo, W., Wu, X., Sun, Y., Gu, Y., Ge, H. M., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.159 · Cited by 33
Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study
van Eijkelenburg, N. K. A., Rasche, M., Ghazaly, E. A., Dworzak, M. N., Klingebiel, T. E., Rössig, C., Leverger, G., Starý, J., de Bont, E. S. J. M., Chitu, D. A., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.187153 · Cited by 33
Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study
Li, J., Gao, J., Liu, A., Liu, W., Xiong, H., Liang, C., Fang, Y., Dai, Y., Shao, J., Yu, H., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02836 · Cited by 31
Self-citation
Retinoic acid, CYP26, and drug resistance in the stem cell niche
Alonso, S., Jones, R. J., & Ghiaur, G. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.07.004 · Cited by 29
The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARα/STAT1 axis
Shao, X., Liu, Y., Li, Y., Xian, M., Zhou, Q., Yang, B., Ying, M., & He, Q. (2016) · Scientific Reports · doi:10.1038/srep24589 · Cited by 27
Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL))
Küley-Bagheri, Y., Kreuzer, K., Monsef, I., Lübbert, M., & Skoetz, N. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011960.pub2 · Cited by 27
Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia
Buteyn, N. J., Fatehchand, K., Santhanam, R., Fang, H., Dettorre, G. M., Gautam, S., Harrington, B. K., Henderson, S. E., Merchand‐Reyes, G., Mo, X. M., et al. (2018) · International Immunology · doi:10.1093/intimm/dxy040 · Cited by 27
Multicomponent assembly of 4-aza-podophyllotoxins: A fast entry to highly selective and potent anti-leukemic agents
Jeedimalla, N., Flint, M., Smith, L., Haces, A., Minond, D., & Roche, S. P. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.10.009 · Cited by 26
Biomodulatory Treatment With Azacitidine, All-trans Retinoic Acid and Pioglitazone Induces Differentiation of Primary AML Blasts Into Neutrophil Like Cells Capable of ROS Production and Phagocytosis
Klobuch, S., Steinberg, T., Bruni, E., Mirbeth, C., Heilmeier, B., Ghibelli, L., Herr, W., Reichle, A., & Thomas, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01380 · Cited by 26
Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling
Sharma, A. K., Yun, H., Jyotsana, N., Chaturvedi, A., Schwarzer, A., Yung, E., Lai, C. K., Kuchenbauer, F. C., Argiropoulos, B., Görlich, K., et al. (2014) · Leukemia · doi:10.1038/leu.2014.162 · Cited by 27
Novel strategies for relapsed and refractory acute myeloid leukemia
Mato, A. R., Morgans, A., & Luger, S. M. (2008) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3282f463d2 · Cited by 26
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review
Megías‐Vericat, J. E., Martínez‐Cuadrón, D., Sanz, M. Á., Poveda, J. L., & Montesinos, P. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1573668 · Cited by 27
Current therapeutic strategies for acute myeloid leukaemia
Kolitz, J. E. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06219.x · Cited by 29
In vivo efficacy of a novel liposomal formulation of safingol in the treatment of acute myeloid leukemia
Tan, K.-B., Ling, L.-U., Bunte, R. M., Chng, W. J., & Chiu, G. N. C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.002 · Cited by 25
The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses
Shallis, R. M., Pollyea, D. A., & Zeidan, A. M. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100806 · Cited by 25
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy
Hütter‐Krönke, M. L., Benner, A., Döhner, K., Krauter, J., Weber, D., Moessner, M., Köhne, C.-H., Horst, H. A., Schmidt‐Wolf, I. G. H., Rummel, M., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.141622 · Cited by 24
Targeting leukemia stem cells
Mikkola, H. K. A., Radu, C. G., & Witte, O. N. (2010) · Nature Biotechnology · doi:10.1038/nbt0310-237 · Cited by 23
The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia
Nazha, A., Bueso-Ramos, C., Estey, E. H., Faderl, S. H., O'Brien, S. M., Fernandez, M. H., Nguyen, M. H., Koller, C. A., Freireich, E. J., Beran, M., et al. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00218 · Cited by 21
Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (APL))
Küley-Bagheri, Y., Kreuzer, K., Engert, A., & Skoetz, N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011960 · Cited by 21
Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities
Stahl, M. F., Kim, T. K., & Zeidan, A. M. (2016) · World Journal of Stem Cells · doi:10.4252/wjsc.v8.i10.316 · Cited by 20
All-trans retinoic acid in anticancer therapy: how nanotechnology can enhance its efficacy and resolve its drawbacks
Borges, G. S. M., Lima, F. A., Carneiro, G., Goulart, G. A. C., & Ferreira, L. A. M. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1919619 · Cited by 21
Overcoming microenvironment-mediated protection from ATRA using CYP26-resistant retinoids
Hernandez, D., Palau, L., Norsworthy, K. J., Anders, N. M., Alonso, S., Su, M., Petkovich, M. P., Chandraratna, R., Rudek, M. A., Smith, B. D., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0790-4 · Cited by 19
Liposomal Codelivery of A Synergistic Combination of Bioactive Lipids in The Treatment of Acute Myeloid Leukemia
Tan, K.-B., Ling, L.-U., Bunte, R. M., Chng, W. J., & Chiu, G. N. (2013) · Nanomedicine · doi:10.2217/nnm.13.123 · Cited by 21
A Pin1/PML/P53 axis activated by retinoic acid in NPM-1c acute myeloid leukemia
Hleihel, R., Hajj, H. E., Wu, H.-C., Berthier, C., Zhu, H., Massoud, R., Chakhachiro, Z. I., El-Sabban, M. E., de Thé, H., & Bazarbachi, A. A. (2021) · Haematologica · doi:10.3324/haematol.2020.274878 · Cited by 17
Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials
Heuser, M., Zapf, A., Morgan, M. A., Krauter, J., & Ganser, A. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1069-z · Cited by 17
Clinical trials: design, endpoints and interpretation of outcomes
Othus, M. K. D., Zhang, M.-J., & Gale, R. P. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01542-0 · Cited by 18
Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1
Paubelle, É., Pleșa, A., Hayette, S., Elhamri, M., Zylbersztejn, F., Hermine, O., Salles, G. A., & Thomas, X. (2019) · Oncology and Therapy · doi:10.1007/s40487-019-0095-9 · Cited by 16
Post-translational modification of retinoic acid receptor alpha and its roles in tumor cell differentiation
Xu, A., Zhang, N., Cao, J., Zhu, H., Yang, B., He, Q., Shao, X., & Ying, M. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113696 · Cited by 15
Consolidation in AML: Abundant opinion and much unknown
Weigert, N., Rowe, J. M., Lazarus, H. M., & Salman, M. Y. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100873 · Cited by 14
Update on Optimal Management of Acute Myeloid Leukemia
Rassi, F. A. E., & Arellano, M. L. (2013) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s8528 · Cited by 14
Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis
Feng, X., Lan, H., Ruan, Y., & Li, C. (2018) · Hematology · doi:10.1080/10245332.2018.1446811 · Cited by 14
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies
Norsworthy, K. J., Cho, E., Arora, J. K., Kowalski, J., Tsai, H., Warlick, E. D., Showel, M. M., Pratz, K. W., Sutherland, L., Gore, S. D., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.09.003 · Cited by 14
Peliosis Hepatis in Cancer Patients Mimicking Infection and Metastases
Wannesson, L., Chigrinova, E. R., Raditchkova, M., Mazzucchelli, L., & Ghielmini, M. E. G. (2009) · Oncology Research and Treatment · doi:10.1159/000184579 · Cited by 13
Treatment strategies for pediatric acute myeloid leukemia
Absalon, M. J., & Smith, F. O. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802627929 · Cited by 13
Improving long-term outcomes with intensive induction chemotherapy for patients with AML
Röllig, C. (2023) · Hematology · doi:10.1182/hematology.2023000504 · Cited by 12
IGFBP7 activates retinoid acid–induced responses in acute myeloid leukemia stem and progenitor cells
van Gils, N., Verhagen, H. J. M. P., Rutten, A. P., de Menezes, R. X., Tsui, M.-L., Vermue, E., Dekens, E., Brocco, F., Denkers, F., Kessler, F. L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002812 · Cited by 11
Phase II study of 2‐chlorodeoxyadenosine plus idarubicin for children with acute myeloid leukaemia in first relapse: a Paediatric Oncology Group study
Chaleff, S., Hurwitz, C. A., Chang, M. N., Dahl, G. V. H., Alonzo, T. A., & Weinstein, H. J. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08976.x · Cited by 12
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML—long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL)
Thiel, A., Schetelig, J., Pönisch, W., Schäfer-Eckart, K., Aulitzky, W. E., Peter, N., Schulze, A., Maschmeyer, G., Neugebauer, S., Herbst, R., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv205 · Cited by 11
Nüks/Refrakter Akut Lösemili Çocuklarda İdarubisin Eklenerek veya Eklenmeden FLAG Tedavisi: Bir Türk Pediatrik Hematoloji Merkezi Deneyimi
Bengoa, Ş. Y., Ataseven, E., Kızmazoğlu, D. Ç., Yenigürbüz, F. D., Erdem, M., & Ören, H. (2016) · Turkish Journal of Hematology · doi:10.4274/tjh.2015.0411 · Cited by 11
Old drug, new use: Recent advances for G-CSF
Yan, L., Li, J., Yang, Y., Zhang, X., & Zhang, C. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156759 · Cited by 11
Mechanisms of chemotherapy failure in refractory/relapsed acute myeloid leukemia: the role of cytarabine resistance and mitochondrial metabolism
Chae, S. Y., Jang, S.-Y., Kim, J., Hwang, S., Malani, D., Kallioniemi, O., Yun, S. G., Kim, H. I., & Kim, H. I. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07653-6 · Cited by 10
Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia
Schlenk, R. F., Weber, D., Krzykalla, J., Kindler, T., Wulf, G. G., Hertenstein, B., Salih, H. R., Südhoff, T., Krauter, J., Martens, U. M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-41964-y · Cited by 10
Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency
Perez, M. W., Sias‐Garcia, O., Daramola, A., Wei, H., Terrell, M., Rashid, R., Park, W. D., Duong, K., Horton, T. M., Li, F., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003737 · Cited by 10
All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 16
Dembitz, V., Lalić, H., Tomić, B., Smoljo, T., Batinić, J., Dubravčić, K., Batinić, D., Bedalov, A., & Višnjić, D. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03224-5 · Cited by 9
Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia
Bug, G., Koschmieder, S., Krauter, J., Heuser, M., Thol, F. R., Wiebe, S., Hofmann, W., Klein, S., Wegener, G., Göhring, G., et al. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1873-3 · Cited by 9
Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper
Dennis, M., Copland, M., Kaur, H., Kell, J., Nikolousis, E., Mehta, P., Palanicawandar, R., Potter, V. T., Raj, K. K., Thomas, I., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18369 · Cited by 8
Is it time to revisit standard post-remission therapy?
Stone, R. M. (2012) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2012.10.006 · Cited by 8
Hematopoietic colony-stimulating factor priming does not influence survival in acute myeloid leukemia: a meta-analysis of randomized trials
Sung, L., Alibhai, S. M. H., Beyene, J., Gamis, A. S., Almeida, R., Smith, S. E., & Aplenc, R. (2008) · Leukemia · doi:10.1038/leu.2008.305 · Cited by 8
A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies
Mosialou, I., Ali, A. M., Labella, R., Bisikirska, B. C., Cuesta‐Domínguez, Á., Vgenopoulou, P., Reyes, I., Rao, S. M., Wang, A., Luo, N., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.007 · Cited by 8

Authors: Milligan, D. W., Wheatley, K., Littlewood, T., Craig, J. I. O., Burnett, A. K., & for the NCRI Haematological Oncology Clinical Studies Group
Affiliations: John Radcliffe Hospital (GB)
ORCID: Wheatley, Keith
Burnett, Alan K.
Venue: Blood
Publisher: American Society of Hematology
Published: 2006-06-15
Volume: 107
Issue: 12
Pages: 4614-4622
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2005-10-4202
OpenAlex: W1984229644
Cited by: 141
References: 49
Citations by year: 2026: 2 · 2025: 3 · 2024: 4 · 2023: 8 · 2022: 4 · 2021: 10 · 2020: 5 · 2019: 5 · 2018: 8 · 2017: 6 · 2016: 11 · 2015: 10 · 2014: 7 · 2013: 8 · 2012: 8
FWCI: 5.26
Type: journal article
Language: en
Open access: closed
Locations: Blood (publishedVersion)
PubMed (publishedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Keywords: high-risk acute myeloid leukemia, fludarabine, cytarabine, daunorubicin, etoposide, filgrastim, granulocyte colony-stimulating factor, all-trans retinoic acid, reinduction chemotherapy, complete remission, disease-free survival, relapse
MeSH terms: Filgrastim, Adolescent, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Daunorubicin, Etoposide, Female, Humans, Male, Middle Aged, Recombinant Proteins, Remission Induction, Retrospective Studies, Risk Factors, Tretinoin, Leukemia, Myeloid, Acute, Survival Rate, Granulocyte Colony-Stimulating Factor, Treatment Outcome, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks